Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends. Maxim Growth Summit in New York: Brian M. Strem, PhD, President and CEO, will speak on an ophthalmology panel titled "A vision of innovation" on October 22, 2025 at 3:00 PM EDT (panel overview link: maximgrp.com/2025-growth-summit).
Eyecelerator @ AAO 2025 in Orlando: Eric Daniels, MD, MBA, Chief Development Officer, will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT (program link: eyecelerator.com/aao-2025-program).
Details
News Market Reaction – KPRX
On Oct 15, the day this news came out, KPRX closed 0.73% below the previous close.
Data tracked by StockTitan Argus for the Oct 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando.
Maxim Growth Summit Ophthalmology Panel Details
Title: A vision of innovation; Advances in biotechnology have spurred innovation in the management of diseases affecting our most used sense
Presenter: Brian M. Strem, PhD, President and Chief Executive Officer
Date & Time: October 22, 2025 at 3:00 pm EDT
More Details: maximgrp.com/2025-growth-summit
Eyecelerator @ AAO 2025 Presentation Details
Session: Poster Retina Showcase
Presenter: Eric Daniels, MD, MBA, Chief Development Officer
Date & Time: October 16, 2025 at 1:45 pm EDT
More Details: eyecelerator.com/aao-2025-program
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contact:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270410
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.